Wave Life Sciences Q1 2025 net loss $46.9M; pipeline progress in obesity, AATD, DMD, HD

Wave Life Sciences Ltd.

2025-Q1 EPS reported -$0.29 revenue$9,175,000

Net loss of $46.9M vs $31.6M prior year; revenue $9.2M (down from $12.5M). Cash $243.1M, runway into 2027.
Obesity: dosing complete in first two INLIGHT cohorts for WVE-007; clinical data expected 2H 2025.
AATD: RestorAATion-2 dosing at 200 mg Q2W and 400 mg single dose; data on multiple cohorts due 3Q and fall 2025.
DMD: Positive 48-week FORWARD-53 data with 3.8 sec improvement in TTR vs natural history; NDA submission planned 2026.
HD: IND submission expected 2H 2025 for potentially registrational Phase 2/3 study of WVE-003.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.